Starling Oncology (STLN) 10% Owner Chernett Jorey Buys Stock

What Happened

• Chernett Jorey, a 10% owner of Starling Oncology (STLN), made a net purchase of common stock: acquired 12,000 shares in an open-market/private purchase on 2026-08-14 at $6.54 per share (total $78,480). The filing also reports a prior disposal of 100 derivative shares on 2026-08-13 at $6.24 (proceeds $624).

Key Details

• Purchase: 12,000 shares @ $6.54 on 2026-08-14 — total cost $78,480.
• Disposal (derivative): 100 shares @ $6.24 on 2026-08-13 — proceeds $624.
• Filing date: Form 4 filed 2026-08-17 (reports transactions dated 2026-08-13 and 2026-08-14).
• Shares owned after the transactions: not specified in the information provided in this summary/filing.
• Footnote: The seller notes the sale of the derivative is a matchable transaction under Section 16(b) and that any short-swing profit calculated will be disgorged to the issuer.

Context

• The purchase is a straightforward buy (often seen as a stronger signal than a sale, but do not infer motive). The 100-share disposal is recorded as a derivative transaction (the filer’s footnote indicates these were call-option related and subject to Section 16(b) short-swing rules). As a 10% owner, Jorey is a significant holder but not necessarily an executive; Section 16 rules and the disgorgement note mean any short-term gains from matched trades will be returned to the company.